このエントリーをはてなブックマークに追加
ID 60759
FullText URL
Author
Senoo, Satoru Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Miyahara, Nobuaki Department of Medical Technology, Okayama University Graduate School of Health Sciences Kaken ID publons researchmap
Taniguchi, Akihiko Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID
Oda, Naohiro Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Itano, Junko Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Higo, Hisao Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hara, Naofumi Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Watanabe, Hiromi Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kano, Hirohisa Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Suwaki, Toshimitsu Department of Respiratory Medicine, Okayama City Hospital
Fuchimoto, Yasuko Department of Respiratory Medicine, Japan Organization of Occupational Health and Safety Okayama Rosai Hospita
Kajimoto, Kazuhiro Department of Respiratory Medicine, Japanese Red Cross Kobe Hospita
Ichikawa, Hirohisa Department of Respiratory Medicine, KKR Takamatsu Hospital
Kudo, Kenichiro Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
Shibayama, Takuo Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
Tanimoto, Yasushi Department of Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center Kaken ID researchmap
Kuyama, Shoichi Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center
Kanehiro, Arihiko Department of Respiratory Medicine, Japan Organization of Occupational Health and Safety Okayama Rosai Hospital Kaken ID publons researchmap
Maeda, Yoshinobu Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID researchmap
Kiura, Katsuyuki Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
Okayama Respiratory Disease Study Group (ORDSG)
Abstract
Background
Nintedanib is a multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF); however, its efficacy and safety for patients with IPF and restricted pulmonary function remain unclear. Therefore, the objective of this study was to determine the efficacy and safety of nintedanib for patients with IPF and forced vital capacity (FVC) ≤ 50%.
Methods
This was a multi-center retrospective study performed by the Okayama Respiratory Disease Study Group. Patients were allocated into FVC ≤ 50% and FVC > 50% groups based on their predicted FVC. The primary endpoints were FVC changes from baseline after 6 and 12 months.
Results
45 patients were eligible for the study. 18 patients had FVC ≤ 50%, and 27 patients had FVC > 50%. Overall, 31 and 19 patients underwent pulmonary function tests at 6 and 12 months after initiating nintedanib, respectively. FVC changes from baseline at 6 and 12 months after initiating nintedanib were comparable between the two groups. Adverse events were seen in all patients, and the rates of patients who discontinued nintedanib were also comparable (38.9% vs. 37.0%, p = 1.000). Multiple regression analysis showed that age and forced expiratory volume in 1 second (FEV1)/FVC were negatively correlated with changes in FVC at 6 months after initiating nintedanib.
Conclusions
Our data suggest that nintedanib can be a useful agent for IPF patients, including those with a low FVC, and that age and FEV1/FVC are predictive markers for changes in FVC following nintedanib treatment.
Published Date
2020-08-27
Publication Title
PLoS ONE
Volume
volume15
Issue
issue8
Publisher
Public Library of Science
Start Page
e0236935
ISSN
1932-6203
Content Type
Journal Article
language
英語
OAI-PMH Set
岡山大学
Copyright Holders
© 2020 Senoo et al.
File Version
publisher
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.1371/journal.pone.0236935
License
https://creativecommons.org/licenses/by/4.0/